Cannabis Law Report

JULY 9, 2021

Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law 105

Law Therapy Clinical Trials Research and Development 105

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

The Cannigma

DECEMBER 12, 2022

It became illegal in the US in 2009. Clinical research: Research is focusing on 5-MeO-DMT use in depression and anxiety. Current clinical trials are underway using a synthetic nasal spray of 5-MeO-DMT in patients with major depressive disorder. As such, there have been numerous clinical trials using ketamine.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

JUNE 11, 2019

Poirier sued following a surgical procedure that left her with chronic pain and limitations affecting her lifestyle and career. Following the incident, Poirier was prescribed numerous medications, but at the time of trial, she was only taking a muscle relaxant and cannabis. Robichaud 4. Siegrist with approval. ” 42.

Chronic Pain 45

Chronic Pain Cannabis History Treatment 45

The Cannigma

JANUARY 13, 2023

3 A 2009 study touched on the trigeminal system as well, examining the connection between the CB1 gene (called CNR1) and people who reported migraines. 5 THC and migraines THC is well-known for its anti-nausea and pain-relieving effects. Ethan Russo details the historical use of cannabis for migraines.

Terpenes 132

Terpenes Strains THC Treatment 132

CannaMD

NOVEMBER 8, 2019

A 2009 Canadian clinical trial of synthetic cannabinoid medication, nabilone , found: The majority of patients (72%) receiving nabilone experienced either cessation of nightmares or a significant reduction in nightmare intensity. Medical marijuana may also play a role in treating nightmares.

Marijuana 85

Marijuana Treatment Research and Development Patients 85

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Pain and chronic pain were the most common conditions mentioned over the time period and were referred to in 62% of all articles.

Research and Development 52

Research and Development Medicine Access Media 52